GlassScriptPhysician profile
Wesley Garland
NPI 1053669416
$1,679.55
in general payments reported to CMS, 2019-2025
13 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.73 · 2020: $20.10 · 2021: $369 · 2022: $212 · 2023: $202 · 2024: $508 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $941.66 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Sight Sciences, INC. | $230.44 | 2021-2023 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $85.54 | 2021-2025 | |
| Amgen INC. | $66.82 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $61.48 | 2024-2025 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $60.57 | 2020-2021 | |
| Abbvie INC. | $44.28 | 2022 | |
| Rxsight INC | $41.10 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $40.76 | 2024 | Xdemvy |
| Thea Pharma INC. | $39.16 | 2023 | Iyuzeh |
| Allergan, INC. | $29.75 | 2021 | |
| Rayner Intraocular Lenses Limited | $19.30 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Biotissue Holdings INC. | $18.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Garland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.